4-Hydroxyphenylretinamide

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Cell permeable: no

Reversible: no

Primary TargetActive in the prevention and treatment of a variety of neoplasms in animals.

Product does not compete with ATP.

General description

A synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity. Active in the prevention and treatment of a variety of neoplasms in animals. Inhibits proliferation in cell lines of human breast cancer, prostate adenocarcinoma, and ovarian carcinoma. Inhibits angiogenesis, as well as endothelial cell motility and tubule formation. Induces apoptosis in malignant hemopoietic cell lines.

A synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity. Active in the prevention and treatment of a variety of neoplasms in animals. Inhibits human breast cancer, prostate adenocarcinoma, and ovarian carcinoma cell proliferation. Inhibits angiogenesis as well as endothelial cell motility and tubule formation. Induces apoptosis in malignant hemopoietic cell lines.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Formelli, F., et al. 1996. FASEB J. 10, 1014.Naik, H.R., et al. 1995. Adv. Pharmacol. 33, 315.Delia, D., et al. 1993. Cancer Res. 53, 6036.Pienta, K.J., et al. 1993. Cancer Res. 53, 224.Grubbs, C.J., et al. 1990. Anticancer Res. 10, 661.McCarthy, D.J., et al. 1987. Cancer Res.47, 5014.Moon, R.C., et al. 1979. Cancer Res.39, 1339.

Packaging

Packaged under inert gas

5 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Harmful & Carcinogenic / Teratogenic (E)